PALO ALTO, Calif. (AP) _ BridgeBio Pharma Inc. (BBIO) on Thursday reported a loss of $60 million in its third quarter.
On a per-share basis, the Palo Alto, California-based company said it had a loss of 51 cents.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 55 cents per share.
The rare disease drug developer posted revenue of $26.7 million in the period.